Data presented at the American Diabetes Association meeting showed that combining Eli Lilly's investigational drug bimagrumab with Novo Nordisk's obesity treatment Wegovy resulted in greater fat loss and preservation of lean tissue compared to Wegovy alone. In a Phase 2b trial, patients on the combination lost an average of 22% body weight over 72 weeks, of which 93% was fat, and experienced a 58% reduction in visceral fat. This compares with 16% weight loss and 72% fat loss in the Wegovy monotherapy group. These findings suggest potential for improved body composition outcomes in obesity management through combination therapies.